<DOC>
	<DOCNO>NCT00005005</DOCNO>
	<brief_summary>This 2-year study test effectiveness combine parathyroid hormone ( PTH ) alendronate treat osteoporosis postmenopausal woman . Alendronate drug use treat osteoporosis primarily prevent bone loss , whereas PTH increase bone formation . We treat study participant either PTH alendronate , alendronate alone , PTH alone . We determine effect treatment look change bone mineral density hip spine .</brief_summary>
	<brief_title>PaTH Study : Parathyroid Hormone Alendronate Osteoporosis</brief_title>
	<detailed_description>The PaTH study 2-year , multicenter , double-blind , placebo-controlled trial test efficacy combine hPTH ( 1-84 ) alendronate treat osteoporosis postmenopausal woman . 238 woman randomize 55 85 year age receive either : ( 1 ) PTH 1 year follow alendronate 1 year ; ( 2 ) PTH alendronate 1 year follow alendronate 1 year ; ( 3 ) alendronate 2 year ; ( 4 ) PTH 1 year follow placebo 1 year . The primary endpoint change bone mineral density several site change biochemical marker . In addition , ass specific biochemical marker bone turnover ( e.g. , osteocalcin , deoxypridinoline , N-telopeptide , bone-specific alkaline phosphatase bone sialoprotein ) determine predict skeletal response combination therapy . We also determine whether PTH positively affect ultrasound measurement calcaneus .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Aged 55 85 year Postmenopausal ( menses last 5 year ) Have bone mineral density scan ( DXA ) evaluate spine AND hip Tscore equal 2.5 spine femoral neck total hip OR Tscore equal 2.0 spine femoral neck total hip least one follow risk factor fracture : ( ) age &gt; 65 year ; ( b ) history postmenopausal fracture ( nonvertebral vertebral ) ; ( c ) maternal history hip fracture Willing able selfadminister daily injection Have use estrogen ( oral patch ) 1 month last 6 month 12 month last 2 year History 12 month bisphosphonate use ever , use ( &gt; 4 week ) within past 12 month History rhPTH ( recombinant human PTH ) use Any major lifethreatening illness Type 1 uncontrolled type 2 diabetes mellitus ( define hemoglobin A1C &gt; 10.0 ) , currently use insulin Vitamin D level &lt; 15 nanograms/ml History kidney disease ( creatinine &gt; 2.0 mg/dl ) Renal insufficiency ( creatinine clearance &lt; 40 mg/min ) Any history kidney stone Any history hypercalciuria currently urine calcium/creatinine &gt; 300 mg History hypercalcemia , sarcoidosis , hyperparathyroidism History active treat tuberculosis granulomatous disorder History breast cancer , melanoma , hematologic malignancy require treatment within last 10 year History bone cancer metabolic bone disease require treatment within last 10 year History nonskin cancer require treatment within last 10 year History symptomatic esophageal reflux , achalasia esophageal stricture Currently take &gt; 7.5 mg systemic prednisone equivalent per day Currently use &gt; two puff , four times/day inhale steroid Currently take anticoagulant anticonvulsant Have use Calcitonin within past 3 month Have use Raloxifene last 6 month 12 month last 2 year Have use Tamoxifen last 6 month 12 month last 2 year Have use fluoride least month within past 5 year Currently take &gt; 1000 IU/day vitamin D vitamin D analogues metabolite Currently take thyroid hormone replacement AND TSH &lt; 0.1mIU/L</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>PTH</keyword>
	<keyword>Alendronate</keyword>
	<keyword>Parathyroid hormone</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Postmenopausal</keyword>
</DOC>